Clinical trials: Vascular Risk
Plaque, Atherosclerotic Disease
BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population
The BioImage Study is a study of the characteristics of subclinical cardiovascular disease, as measured by imaging modalities, unsupervised circulating biomarker measurements, and risk factors that predict progression to overt…
- Conditions
- Plaque, Atherosclerotic Disease, Heart Disease, Stroke
- Trial name
- NCT00738725
- Where
- 2 sites in United States
- Volunteers
- 7,687 people, healthy volunteers welcome
- Sponsor
- BG Medicine, Inc
Acute Coronary Syndrome
Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture
Atherosclerosis is a progressive inflammatory disease of the large and medium sized arteries, which is characterized by the formation of plaques in the vessel wall.
- Trial name
- ICEBERG (NCT04857580)
- Testing
- CTS Device
- Where
- 3 sites in Denmark, Sweden
- Sponsor
- Cryotherapeutics SA
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prematurity, Vascular Aging
Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
- Trial name
- NEOVASC (NCT04413994)
- Testing
- Humavant
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Prolacta Bioscience
Surgical Wound Healing, Lower Extremity
Oxygen for Vascular Incisional Healing
The purpose of this clinical trial is to evaluate Transdermal Continuous Oxygen Therapy (TCOT) as an adjunct to surgical wound healing in subjects undergoing vascular surgery for lower extremity arterial occlusive disease.
- Conditions
- Surgical Wound Healing, Lower Extremity, Revascularization, Incision
- Trial name
- NCT03746132
- Testing
- EPIFLO
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neogenix, LLC dba Ogenix
Atherosclerotic Cardiovascular Disease
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients.
- Trial name
- BETTER (NCT05761444)
- Testing
- Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg
- Where
- 7 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Carotid Artery Stenosis
GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)
Compare the 30-day safety and efficacy of the GORE® Embolic Filter used in conjunction with FDA-approved carotid stents to a performance goal obtained from carotid stent studies utilizing distal embolic protection.
- Trial name
- EMBOLDEN (NCT00766493)
- Testing
- GORE® Embolic Filter
- Volunteers
- 250 people
- Sponsor
- W.L.Gore & Associates
Coronary Artery Disease
SHIELD II Clinical Investigation
The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with…
- Trial name
- SHIELD II (NCT02468778)
- Testing
- HeartMate PHP, Any Abiomed Impella® device approved for use in high-risk PCI
- Where
- 58 sites in United States
- Volunteers
- 54 people
- Sponsor
- Abbott Medical Devices
Myocardial Infarction, Arrhythmia, Ventricular
MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
The purpose of the study is to determine the usefulness of microvolt T wave alternans (MTWA) testing of patients that have had a heart attack and have decreased pumping ability of the lower chamber of their heart.
- Conditions
- Myocardial Infarction, Arrhythmia, Ventricular, Ischemic Cardiomyopathy
- Trial name
- NCT00305240
- Testing
- T Wave Alternans Test
- Where
- 47 sites in United States
- Volunteers
- 656 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atherosclerosis
Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis
This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.
- Trial name
- NCT01287182
- Testing
- Ateronon
- Where
- Lebanon
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Omicron Pharmaceuticals
Secondary Prevention, Stroke
Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
To investigate the risk of major bleeding (including gastrointestinal and intracranial bleeding episodes) among new users of low-dose acetylsalicylic acid (ASA) in clinical practice
- Conditions
- Secondary Prevention, Stroke, Ischemic Heart Disease, Coronary Heart Disease
- Trial name
- EPISAT (NCT02550717)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465), Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
- Where
- United Kingdom
- Volunteers
- 398,158 people
- Sponsor
- Bayer
Smoldering Multiple Myeloma (SMM)
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing Multiple Myeloma (MM), a group commonly labeled as High-Risk Smoldering Multiple Myeloma (HR-SMM).
- Trial name
- NCT05955508
- Testing
- Linvoseltamab
- Where
- 17 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Coronary Artery Disease
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
- Trial name
- NCT06445608
- Testing
- Percutaneous Mechanical Circulatory Support
- Where
- 18 sites in United States
- Volunteers
- 310 people
- Sponsor
- Kardion Inc
Hypertension, Cardiovascular Risk
Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Prediction of Cardiovascular Risk
Because Aktiia S.A. has been the first-ever company to put in the market an Optical Blood Pressure Monitoring device, there is a need for Aktiia S.A.
- Conditions
- Hypertension, Cardiovascular Risk, Blood Pressure Check (Hypertension Screening)
- Trial name
- FORESEE2024 (NCT06670677)
- Testing
- Lifestyle survey completion, Unlimited on-demand blood pressure measurements with G2C, Continual blood pressure measurements with G1
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Aktiia SA
CAD - Coronary Artery Disease
REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease
REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in…
- Trial name
- REWRITE-CAD (NCT07834372)
- Testing
- Heartflow Analysis
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- HeartFlow, Inc.
Psoriasis, Inflammation
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
- Conditions
- Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
- Trial name
- NCT04776629
- Testing
- Orticumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Abcentra
Coronary Artery Disease
A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)
The purpose of this trial is to evaluate the clinical safety and effectiveness of the Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month DAPT treatment receiving…
- Trial name
- Onyx ONE Clear (NCT03647475)
- Testing
- Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
- Where
- 4 sites in United States
- Volunteers
- 752 people
- Sponsor
- Medtronic Vascular
Acute Coronary Syndrome
A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis
To characterize and estimate the size of different populations with a history of acute coronary syndrome in Sweden. To assess the burden of illness (co-morbidities, mortality rates healthcare resource utilization and…
- Trial name
- HELICON (NCT01984307)
- Where
- Sweden
- Volunteers
- 100,000 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM).
- Trial name
- NCT05882279
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 330 people
- Sponsor
- Takeda
Hypotension
Clinical Validation of Vital-PICASO for Predicting Hypotension Within 24 Hours in General Ward Inpatients
This retrospective study evaluated the clinical performance of Vital-PICASO, an artificial intelligence-based biological signal analysis software designed to predict the risk of hypotension within 24 hours using vital-sign data…
- Trial name
- NCT07742930
- Where
- South Korea
- Volunteers
- 648 people
- Sponsor
- Huinno AIM